Identification of BACE1 inhibitors from Panax ginseng saponins-An Insilco approach

Computers in Biology and Medicine

Volumn 43, Issue 8, 2013, Pages 1037-1044

  Karpagam, Veerappan ^b   Sathishkumar, Natarajan ^a   Sathiyamoorthy, Subramaniyam ^a   Rasappan, Periannan ^b   Shila, Samuel ^b   Kim, Yeon Ju ^a   Yang, Deok Chun ^a  

^a Kyung Hee University   (South Korea)

^b Department of Biochemistry   (India)

Author keywords

Alzheimer's disease; BACE1; Ginsenosides; Molecular modeling; Panax Ginseng

Indexed keywords

ALZHEIMER'S DISEASE; BACE1; BLOOD-BRAIN BARRIER; EXPERIMENTAL EVIDENCE; GINSENOSIDES; HYDROGEN BOND INTERACTION; MOLECULAR DYNAMICS SIMULATIONS; PANAX GINSENG;

HYDROGEN BONDS; MOLECULAR DYNAMICS;

MOLECULAR MODELING;

BETA SECRETASE 1; BETA SECRETASE INHIBITOR; CHIKUSETSU SAPONIN; GINSENOSIDE; GINSENOSIDE CK; GINSENOSIDE F1; GINSENOSIDE RB 1; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RF; GINSENOSIDE RG 1; GINSENOSIDE RG 2; GINSENOSIDE RG 3; GINSENOSIDE RH 1; GINSENOSIDE RH 2; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; DRUG IDENTIFICATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; GINSENG; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL;

AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; CATALYTIC DOMAIN; DRUG STABILITY; ENZYME INHIBITORS; GINSENOSIDES; HUMANS; HYDROGEN BONDING; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PANAX; THERMODYNAMICS;

PANAX GINSENG;

EID: 84879452623     PISSN: 00104825     EISSN: 18790534     Source Type: Journal    
DOI: 10.1016/j.compbiomed.2013.05.009     Document Type: Article

References (53)

1. Shen L.L., Liu G.X., Tang Y. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors. Acta Pharmacol. Sin. 2007, 28:2053-2063.
2. Crews L., Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum. Mol. Genet. 2010, 19:R12-20.
3. Alzheimer's Dementia: J. Alzheimer's Assoc. 2012, 8:131-168.
4. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid [beta]-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
5. Lazarov O., Marr R.A. Neurogenesis and Alzheimer's disease: at the crossroads. Exp. Neurol. 2010, 223:267-281.
6. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
7. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
8. De Strooper B., Vassar R., Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:99-107.
9. Wilquet V., De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Curr. Opinion Neurobiol. 2004, 14:582-588.
10. Hussain I., Powell D., Howlett D.R., Tew D.G., Meek T.D., Chapman C., Gloger I.S., Murphy K.E., Southan C.D., Ryan D.M., Smith T.S., Simmons D.L., Walsh F.S., Dingwall C., Christie G. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell Neurosci. 1999, 14:419-427.
11. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
12. Dominguez D., Tournoy J., Hartmann D., Huth T., Cryns K., Deforce S., Serneels L., Camacho I.E., Marjaux E., Craessaerts K., Roebroek A.J., Schwake M., D'Hooge R., Bach P., Kalinke U., Moechars D., Alzheimer C., Reiss K., Saftig P., De Strooper B. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J. Biol. Chem. 2005, 280:30797-30806.
13. Roberds S.L., Anderson J., Basi G., Bienkowski M.J., Branstetter D.G., Chen K.S., Freedman S.B., Frigon N.L., Games D., Hu K., Johnson-Wood K., Kappenman K.E., Kawabe T.T., Kola I., Kuehn R., Lee M., Liu W., Motter R., Nichols N.F., Power M., Robertson D.W., Schenk D., Schoor M., Shopp G.M., Shuck M.E., Sinha S., Svensson K.A., Tatsuno G., Tintrup H., Wijsman J., Wright S., McConlogue L. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 2001, 10:1317-1324.
14. Basi G., Frigon N., Barbour R., Doan T., Gordon G., McConlogue L., Sinha S., Zeller M. Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells. J. Biol. Chem. 2003, 278:31512-31520.
15. Farzan M., Schnitzler C.E., Vasilieva N., Leung D., Choe H. BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. Proc. Natl. Acad. Sci. 2000, 97:9712-9717.
16. Lin X., Koelsch G., Wu S., Downs D., Dashti A., Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc. Natl. Acad. Sci. USA 2000, 97:1456-1460.
17. Sinha S., Anderson J.P., Barbour R., Basi G.S., Caccavello R., Davis D., Doan M., Dovey H.F., Frigon N., Hong J., Jacobson-Croak K., Jewett N., Keim P., Knops J., Lieberburg I., Power M., Tan H., Tatsuno G., Tung J., Schenk D., Seubert P., Suomensaari S.M., Wang S., Walker D., Zhao J., McConlogue L., John V. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999, 402:537-540.
18. Koehn F.E., Carter G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug. Discovery 2005, 4:206-220.
19. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70:461-477.
20. Park S.Y. Potential therapeutic agents against Alzheimer's disease from natural sources. Arch. Pharm. Res. 2010, 33:1589-1609.
21. Yun T.K. Brief introduction of Panax ginseng C.A. Meyer. J. Korean Med. Sci. 2001, 16(Suppl.):S3-5.
22. Choi K.T. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C.A. Meyer. Acta Pharmacol. Sin. 2008, 29:1109-1118.
23. Leung K.W., Wong A.S. Pharmacology of ginsenosides: a literature review. Chin. Med. 2010, 5:20.
24. C.-S.P. Je-Yong Kang, Sung-Ryong Ko, Kyo In, Chol-Soo Park, Dong-Yun Lee, Deok-Chun Yang, Characteristics of absorption and accumulation of inorganic Germanium in Panax ginseng C.A. Meyer, J. Ginseng Res. 35 (2011) 12-20.
25. Radad K., Moldzio R., Rausch W.D. Ginsenosides and their CNS targets. CNS Neurosci. Ther. 2011, 17:761-768.
26. Roh Y.S., Kim H.B., Kang C.W., Kim B.S., Nah S.Y., Kim J.H. Neuroprotective effects of ginsenoside Rg3 against 24-OH-cholesterol-induced cytotoxicity in cortical neurons. J. Ginseng Res. 2010, 34:246-253.
27. Li N., Liu B., Dluzen D.E., Jin Y. Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J. Ethnopharmacol. 2007, 111:458-463.
28. Ye R., Han J., Kong X., Zhao L., Cao R., Rao Z., Zhao G. Protective effects of ginsenoside Rd on PC12 cells against hydrogen peroxide. Biol. Pharm. Bull. 2008, 31:1923-1927.
29. Xie X., Wang H.T., Li C.L., Gao X.H., Ding J.L., Zhao H.H., Lu Y.L. Ginsenoside Rb1 protects PC12 cells against beta-amyloid-induced cell injury. Mol. Med. Rep. 2010, 3:635-639.
30. Wang Y.H., Du, Ginsenoside Rg1 G.H. inhibits beta-secretase activity in vitro and protects against Abeta-induced cytotoxicity in PC12 cells. J. Asian Nat. Prod. Res. 2009, 11:604-612.
31. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4:187-217.
32. Vanommeslaeghe K., Hatcher E., Acharya C., Kundu S., Zhong S., Shim J., Darian E., Guvench O., Lopes P., Vorobyov I., Mackerell A.D. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 2010, 31:671-690.
33. Berman H.M., Battistuz T., Bhat T.N., Bluhm W.F., Bourne P.E., Burkhardt K., Feng Z., Gilliland G.L., Iype L., Jain S., Fagan P., Marvin J., Padilla D., Ravichandran V., Schneider B., Thanki N., Weissig H., Westbrook J.D., Zardecki C. The Protein Data Bank. Acta Crystallogr. D. Biol. Crystallogr. 2002, 58:899-907.
34. Bernstein F.C., Koetzle T.F., Williams G.J., Meyer E.F., Brice M.D., Rodgers J.R., Kennard O., Shimanouchi T., Tasumi M. The protein data bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 1977, 112:535-542.
35. Iserloh U., Wu Y., Cumming J.N., Pan J., Wang L.Y., Stamford A.W., Kennedy M.E., Kuvelkar R., Chen X., Parker E.M., Strickland C., Voigt J. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:414-417.
36. Vassar R. β-Secretase (BACE) as a drug target for Alzheimer's disease. Adv. Drug Delivery Rev. 2002, 54:1589-1602.
37. Ma D.-L., Chan D.S.-H., Leung C.-H. Molecular docking for virtual screening of natural product databases. Chem. Sci. 2011, 2:1656-1665.
38. Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31:455-461.
39. Sathishkumar N., Sathiyamoorthy S., Ramya M., Yang D.U., Lee H.N., Yang D.C. Molecular docking studies of anti-apoptotic BCL-2, BCL-XL, and MCL-1 proteins with ginsenosides from Panax ginseng. J. Enzyme Inhib. Med. Chem. 2012, 27:685-692.
40. Stierand K., Rarey M. Drawing the PDB: protein-ligand complexes in two dimensions. ACS Med. Chem. Lett. 2010, 1:540-545.
41. Stierand K., Rarey M. Poseview-molecular interaction patterns at a glance. J. Cheminf. 2010, 2:P50.
42. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23:3-25.
43. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46:3-26.
44. Van Der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A.E., Berendsen H.J. GROMACS: fast, flexible, and free. J. Comput. Chem. 2005, 26:1701-1718.
45. Christen M., Hunenberger P.H., Bakowies D., Baron R., Burgi R., Geerke D.P., Heinz T.N., Kastenholz M.A., Krautler V., Oostenbrink C., Peter C., Trzesniak D., van Gunsteren W.F. The GROMOS software for biomolecular simulation: GROMOS05. J. Comput. Chem. 2005, 26:1719-1751.
46. Ljungh Å., Moran A.P., Wadström T. Interactions of bacterial adhesins with extracellular matrix and plasma proteins: pathogenic implications and therapeutic possibilities. FEMS Immunol. Med. Microbiol. 1996, 16:117-126.
47. Schuttelkopf A.W., van Aalten D.M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D. Biol. Crystallogr. 2004, 60:1355-1363.
48. Hess B., Bekker H., Berendsen H.J.C., Fraaije J.G.E.M. LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 1997, 18:1463-1472.
49. Sathishkumar N., Sathiyamoorthy S., Ramya M., Yang D.U., Lee H.N., Yang D.C. Molecular docking studies of anti-apoptotic BCL-2, BCL-XL, and MCL-1 proteins with ginsenosides from Panax ginseng, Accelrys. Accelrys Discovery Studio 2.5, San Diego, CA. 2009. J. Enzyme Inhib. Med. Chem. 2011.
50. Moroy G., Martiny V.Y., Vayer P., Villoutreix B.O., Miteva M.A. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discovery Today 2012, 17:44-55.
51. Hou T., Wang J., Zhang W., Wang W., Xu X. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr. Med. Chem. 2006, 13:2653-2667.
52. Mohan C.G., Gandhi T., Garg D., Shinde R. Computer-assisted methods in chemical toxicity prediction. Mini-Rev. Med. Chem. 2007, 7:499-507.
53. Sathishkumar N., Karpagam V., Sathiyamoorthy S., Woo M.J., Kim Y.-J., Yang D.-C. Computer-aided identification of EGFR tyrosine kinase inhibitors using ginsenosides from Panax ginseng. Comput. Biol. Med. 2013, 43:786-797.